The LDL Study

Study duration: 3-night inpatient stay, 16 follow-up visits.

Reimbursement: $8,500

Inpatient Stay: Tuesday 3rd December - Friday 6th December, 2024.

Follow-up visits will continue until end February 2025 (+/- 3 days). To support your participation, you will receive progress payments throughout the study.

Study Objective:

• The objective of this study is to evaluate a potential new treatment that aims to reduce LDL-C (Low-Density Lipoprotein Cholesterol), also known as the “bad cholesterol.”
• The study medication is a potential new treatment for non-alcoholic fatty liver disease, the most common chronic liver disease in the world. It targets the metabolic pathway of LDL cholesterol, which is why we are recruiting participants with elevated LDL cholesterol.
• Participants will receive one dose of the study medication or a placebo which is administered via subcutaneous injection.

Understanding LDL:

• LDL stands for low-density lipoprotein, often referred to as “bad” cholesterol. It carries cholesterol to various cells in the body. However, high levels of LDL can lead to plaque buildup in the arteries, a condition known as atherosclerosis. This can increase the risk of heart disease and stroke.

Importance of Treatment:

• While statins, a type of cholesterol-lowering drug, have been a key treatment for cardiovascular disease. Not all patients respond well or tolerate them due to the side effects. This highlights the importance of finding additional treatment options, to help these patients manage their cholesterol levels effectively.

Volunteers required: 

• Male or Female
• 18-55 years old
• BMI 30-40 kg/m2
• Stable body weight (no major fluctuations)
• No significant medical history (except for elevated cholesterol)
• Not taking any medication (except for hormonal contraception)
• Non-smokers and moderate smokers only (<5 cigarettes/day)

Ready to learn more? Give us a call to discuss the studies and book your screening appointment or click the button below!

Call us on
1300 517 998